Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer.

Nuzhat SialSaba SaeedMukhtiar AhmadYasir HameedAbdul RehmanMustansar AbbasRizwan AsifHamad AhmedMuhammad Safdar HussainJalil Ur RehmanMuhammad AtifMuhammad Rashid Khan

Published in: International journal of general medicine (2021)

In conclusion, via this in silico study, we have elucidated that TMED2 can serve as a shared diagnostic and prognostic biomarker in CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients of different clinicopathological features but, further in vitro and in vivo research should be carried out to confirm these findings.

Keyphrases

end stage renal disease
endothelial cells
newly diagnosed
chronic kidney disease
prognostic factors
molecular docking
patient reported outcomes
squamous cell
pluripotent stem cells
patient reported